BioSpace News Archive

Vicinitas Therapeutics today announced the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer.

Taysha Gene Therapies, Inc. today announced the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Shape Therapeutics Inc., a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer.

60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in treating babesiosis.

Mineralys Therapeutics, Inc. today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.

Provectus Biopharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “ Composition and Method for Oral Treatment of Leukemia ”).

Akoya Biosciences, Inc., The Spatial Biology Company®, and Shanghai KR Pharmtech have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China’s National Medical Products Administration to support next generation pathology clinical workflows.

Science 37 Holdings, Inc. disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

PDS Biotechnology Corporation announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer, effective as of May 1, 2024.

NewAmsterdam Pharma Company N.V. announced that it will host an R&D Day event for analysts and investors on May 16, 2024 beginning at 9:00 a.m. ET in New York City.